Walter Stockinger
Private Equity Investor chez Hadean Ventures AS
Profil
Walter Stockinger is currently the Managing Partner at Hadean Ventures.
AS since 2016.
Prior to this, he was a Board Member & Investor Director at Opsona Therapeutics Ltd.
Dr. Stockinger received his graduate and doctorate degrees from the University of Vienna.
Postes actifs de Walter Stockinger
| Sociétés | Poste | Début |
|---|---|---|
Hadean Ventures AS
 Hadean Ventures AS Investment ManagersFinance Hadean Ventures AS (Hadean Ventures) is a venture capital firm that manages alternative investment funds. The firm was founded by Ingrid Helene Teigland Akay in 2014 and is headquartered in Oslo, Norway. | Private Equity Investor | 01/05/2016 |
Anciens postes connus de Walter Stockinger
| Sociétés | Poste | Fin |
|---|---|---|
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Directeur en chef des Investissements | - |
Formation de Walter Stockinger
| University of Vienna | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Hadean Ventures AS
Hadean Ventures AS Investment ManagersFinance Hadean Ventures AS (Hadean Ventures) is a venture capital firm that manages alternative investment funds. The firm was founded by Ingrid Helene Teigland Akay in 2014 and is headquartered in Oslo, Norway. | Finance |
